3D bioprinting goes from research to commercial products

摘要

Ink-jet making of biomolecules such as proteins, enzymes, antibodies, and DNA was first achieved in 1988, and by 2004 ink-jet printing of mammalian cells was possible. This 3D bioprinting allows the cells to have the right association and compartmentalization, so that the performance and behavior of the tissue is representative of the whole. The synergis-tic effect of the interaction between cells mean they live much longer than when they are separate. An explosion of interest this year is driving commercialization of bioprinting. According to IDTechEx research, the 3D bioprinting market will reach $6 billion by 2024.